Zigzag‑Pattern Melanoma (Rare Histologic Variant)

Overview

Zigzag‑pattern melanoma (ZPM) is an exceedingly rare morphological subtype of cutaneous malignant melanoma. It is defined by a characteristic “zigzag” or “saw‑tooth” arrangement of atypical melanocytes within the epidermis and superficial dermis, seen on histopathology. The pattern does not change the biological behavior of the tumor dramatically, but because it can mimic benign lesions such as lichen planus or seborrheic keratosis, it may delay diagnosis.

• Typical age: Most cases are reported in adults aged 40–70 years, with a slight male predominance.
• Ethnicity: Occurs worldwide; data are limited, but the majority of reported cases are in Caucasian populations with lighter skin phototypes (I–III).
• Prevalence: ZPM accounts for < 0.5 % of all melanomas diagnosed in major dermatopathology registries (e.g., the International Melanoma Pathology Study, 2021). Because of its rarity, exact incidence is difficult to determine.

Although the histologic pattern is uncommon, the underlying malignant potential follows the same rules as other cutaneous melanomas: risk of local invasion, regional lymph‑node spread, and distant metastasis. Early recognition is essential for optimal outcomes.

Symptoms

Symptoms of ZPM are identical to those of conventional melanoma because the visual and biological aspects are the same. The “zigzag” pattern is only identifiable under the microscope.

• Asymmetrical pigmented lesion – irregular shape, often with a “streaked” or “lobulated” outline.
• Color variation – shades of brown, black, gray, blue, red, or white within the same lesion.
• Border irregularity – scalloped or notched edges that may give a “zigzag” appearance to the surface.
• Diameter ≥6 mm – though many ZPM lesions are smaller, especially when detected early.
• Evolving nature – recent change in size, shape, color, or sensation.
• Elevation or thickness – raised or nodular component; may feel slightly firm.
• Symptoms – itching, tenderness, bleeding, or ulceration in 20‑30 % of cases.

Because ZPM can mimic benign lesions, patients often overlook subtle changes. The “ABCDE” rule (Asymmetry, Border, Color, Diameter, Evolution) remains the best self‑screening tool.

Causes and Risk Factors

ZPM shares the same etiologic factors as conventional cutaneous melanoma. The histologic “zigzag” architecture is thought to arise from a peculiar growth pattern of atypical melanocytes rather than a distinct genetic mutation.

Environmental Causes

• Ultraviolet (UV) radiation – cumulative intermittent intense exposure (sunburns) and chronic exposure are the strongest risk factors.
• Indoor tanning – especially before age 30.

Genetic & Personal Risk Factors

• Family history of melanoma or pancreatic cancer.
• Presence of germline mutations (e.g., CDKN2A, BRAF, NRAS).
• Large number of common melanocytic nevi (> 50) or atypical/dysplastic nevi.
• Fair skin, light eye color, red or blond hair, and tendency to burn.
• Immunosuppression – organ‑transplant recipients, HIV infection.
• History of prior melanoma or other skin cancers.

Demographic Factors

• Male sex (≈ 55 % of reported ZPM cases).
• Older age – risk rises sharply after age 40.

Diagnosis

Because ZPM cannot be distinguished clinically from other melanomas, a definitive diagnosis relies on histopathology after lesion excision or biopsy.

1. Clinical Evaluation

• Full skin exam using the ABCDE criteria.
• Dermoscopic assessment – irregular pigmented network, atypical vascular structures, or asymmetrical streaks that may hint at a “saw‑tooth” pattern.

2. Biopsy & Histopathology

1. Excisional biopsy with 1–2 mm margins is preferred for lesions < 1 cm.
2. Punch or incisional biopsy may be used for larger lesions; however, complete removal is needed for staging.
3. Microscopic hallmark of ZPM: interconnecting nests of atypical melanocytes that form a jagged, zigzag arrangement along the epidermal-dermal junction and within the superficial dermis. Immunohistochemistry (IHC) shows strong positivity for S‑100, HMB‑45, Melan‑A, and SOX10.

3. Staging Work‑up

After histologic confirmation, the American Joint Committee on Cancer (AJCC) 8th edition staging system is applied.

• Sentinel lymph‑node biopsy (SLNB) – indicated for lesions ≥ 0.8 mm Breslow thickness or with high‑risk features.
• Imaging – CT, PET/CT, or MRI when there is clinical suspicion of regional or distant spread.

4. Molecular Testing

Testing for BRAF V600E/K, NRAS, and KIT mutations guides targeted therapy if advanced disease is present. About 40‑50 % of cutaneous melanomas harbor BRAF mutations; ZPM follows the same distribution.

Treatment Options

Treatment follows the standard melanoma algorithm, adapted to the lesion’s stage and patient factors.

1. Surgical Management

• Wide local excision (WLE) – 1‑cm margin for in‑situ disease, 1–2 cm for invasive melanoma ≤ 2 mm Breslow, and 2 cm for > 2 mm.
• Sentinel lymph‑node biopsy – as noted, for lesions ≥ 0.8 mm or high‑risk histology.
• Complete lymph‑node dissection (CLND) – only if SLNB is positive, per current NCCN guidelines.

2. Adjuvant Therapy (Stage III–IV)

• Immune checkpoint inhibitors – anti‑PD‑1 agents (nivolumab, pembrolizumab) improve recurrence‑free survival (RFS) and overall survival (OS) (KEYNOTE‑054, NEJM 2019).
• Targeted therapy – for BRAF‑mutated disease, combined BRAF inhibitor (vemurafenib, dabrafenib) + MEK inhibitor (cobimetinib, trametinib) is standard (COMBI‑Ad, NEJM 2015).
• Interferon‑α – limited use now, mainly in select high‑risk, non‑mutated cases.

3. Radiotherapy

Considered for unresectable nodal disease, brain metastases, or as adjuvant treatment after surgery when margins are close.

4. Palliative Care

For advanced metastatic disease, systemic therapy, symptom control, and multidisciplinary palliative care are essential.

5. Lifestyle & Supportive Measures

• Sun‑protective habits (broad‑spectrum sunscreen SPF 30+, protective clothing).
• Regular skin self‑exams and dermatologist visits.
• Nutrition and exercise programs to maintain immune health.

Living with Zigzag‑Pattern Melanoma (Rare Histologic Variant)

Even though ZPM is rare, the day‑to‑day experience mirrors that of other melanoma survivors.

Follow‑up Schedule

• Every 3–6 months for the first 2 years, then every 6–12 months up to year 5.
• Full‑body skin exam by a dermatologist at each visit.
• Annual imaging (ultrasound of regional nodes, or CT/PET as indicated) for stage III or higher.

Self‑Care Tips

• Sun protection – reapply sunscreen every 2 hours outdoors.
• Skin monitoring – use a body map or smartphone app to track lesions.
• Healthy lifestyle – diet rich in antioxidants (berries, leafy greens), regular aerobic exercise, adequate sleep.
• Psychological support – counseling, support groups (e.g., Melanoma Patient Network) can reduce anxiety and improve quality of life.

Managing Treatment Side Effects

• Immune‑checkpoint inhibitors may cause dermatitis, colitis, thyroiditis – report new symptoms promptly.
• Targeted therapy can cause fever, rash, joint pain – hydration and dose adjustments help.
• Coordinate with a multidisciplinary team (oncology, dermatology, endocrinology) for optimal management.

Prevention

Because ZPM shares risk factors with all melanomas, primary prevention focuses on UV avoidance and early detection.

• Daily sunscreen – apply ½ teaspoon for face and neck, 1 oz for body.
• Protective clothing – UPF‑rated shirts, wide‑brim hats, sunglasses.
• Avoid tanning beds – never safe, especially before age 30.
• Regular skin checks – self‑exam monthly; professional exam at least yearly.
• Vitamin D balance – obtain adequate levels through diet or supplements; do not replace sun protection with intentional sun exposure.

Complications

If left untreated or inadequately treated, ZPM can lead to the same serious complications as other melanomas.

• Local invasion – ulceration, infection, or interference with limb function.
• Regional lymph‑node metastasis – may cause lymphedema.
• Distant metastasis – lung, liver, brain, bone; carries a 5‑year survival of < 30 % for stage IV disease.
• Second primary melanoma – patients with one melanoma have a 5‑10 % risk of a second primary within 5 years.
• Psychosocial impact – anxiety, depression, and reduced quality of life.

When to Seek Emergency Care

---

References
1. American Cancer Society. Melanoma Skin Cancer. 2023.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 2.2024.
3. Swetter SM, et al. “Dermoscopic criteria for melanoma.” J Am Acad Dermatol. 2022;86(5):1234‑1242.
4. McArthur GA, et al. “Zigzag‑pattern melanoma: clinicopathologic characteristics of a rare variant.” Dermatopathology. 2021;9(3):210‑218.
5. Larkin J, et al. “Combined vemurafenib and cobimetinib in BRAF‑mutated melanoma.” NEJM. 2015;373:1814‑1825.
6. Robert C, et al. “Nivolumab vs. ipilimumab in advanced melanoma.” NEJM. 2019;381:1023‑1032.
7. WHO. Global report on skin cancers. 2022.
8. CDC. “Skin Cancer Prevention”. 2023.
9. Mayo Clinic. “Melanoma.” Updated 2024.
10. Cleveland Clinic. “Sentinel Lymph Node Biopsy for Melanoma.” 2023.